WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Executive Summary TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a ...
TScan Therapeutics operates in the U.S. Small & Mid Cap Biotechnology sector, concentrating on innovative therapies for both hematological malignancies and solid tumors. The company’s primary focus ...
(MENAFN- GlobeNewsWire - Nasdaq) Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results